1. Health technology

  2. •

    Pharmaceuticals: major
AtaiBeckley Inc.

AtaiBeckley Inc.

GGETTEX:B72
6.30
EUR
0.00
(0.00%)
-1.87EPS
1.72BMarket Cap
AtaiBeckley Inc.
GETTEX:B72
(Gettex)

Recent

price

6.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
0.15
- -
- -
- -
0.02
0.01
Revenue per Share
-0.09
-1.11
-1.21
-0.98
-0.25
-0.93
-2.91
-2.14
Basic EPS, GAAP
-0.05
-0.14
-0.46
-0.68
-0.53
-0.51
-0.5
-0.39
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.39
0.6
2.35
1.57
1.46
0.69
0.61
0.48
Book Value per Share
0.39
0.6
2.35
1.57
1.45
0.67
0.6
0.47
Tangible Book Value per Share
153
153
138
156
159
160
227
313
Basic Weighted Avg Shares
- -
- -
20
- -
- -
- -
4
4
Sales/Revenue/Turnover
- -
- -
-590.52
-61,987.12
-39,180.25
-33,170.78
-2,772
-3,121.86
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
Depreciation Expense
-14
-170
-168
-152
-40
-149
-660
-668
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-823.56
-65,401.29
-12,810.19
-48,463.96
-16,142.02
-14,938.36
Profit Margin (%)
38
87
354
267
165
55
252
216
Working Capital
- -
2
1
15
19
15
2
2
LT Debt
60
95
386
266
244
117
222
176
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-227.1
-71.75
-47.8
-15.97
-83.1
-390.36
-417.48
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
363
366
369
Market Capitalization
- -
1,293
1,966

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
276
250
245
Cash, Cash Equivalents & STI
256
231
226
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
23
25
29
Payables & Accruals
19
20
25
ST Debt
- -
- -
- -
Deferred Revenue
2
1
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
60.73%
90.47%
Free Cash Flow
- -
57.22%
37.72%
Net Income, GAAP
- -
105.86%
342.19%
Sales/Revenue/Turnover
- -
- -
1,227.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
2
1
1
1
4
2026
1
2
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.36
-0.16
-0.24
-0.93
2025
-0.15
-0.14
-0.28
-1.73
-2.91
2026
-0.08
-0.09
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business